Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 34904798

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2022 Feb 17
First author
Bishop MR

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2022 Feb 17;386(7):692-696. doi: 10.1056/NEJMe2118899.
    note
    Source null
    related pmid
    34904797
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Feb;19(2):71. doi: 10.1038/s41571-021-00598-7.
    note
    Source null
    related pmid
    34987189
    relationship
    Comment in

Authors and identifiers

  1. name
    Bishop MR
    type
    Author
  2. name
    Dickinson M
    type
    Author
  3. name
    Purtill D
    type
    Author
  4. name
    Barba P
    type
    Author
  5. name
    Santoro A
    type
    Author
  6. name
    Hamad N
    type
    Author
  7. name
    Kato K
    type
    Author
  8. name
    Sureda A
    type
    Author
  9. name
    Greil R
    type
    Author
  10. name
    Thieblemont C
    type
    Author
  11. name
    Morschhauser F
    type
    Author
  12. name
    Janz M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Bishop MR
    type
    Author
  2. name
    Dickinson M
    type
    Author
  3. name
    Purtill D
    type
    Author
  4. name
    Barba P
    type
    Author
  5. name
    Santoro A
    type
    Author
  6. name
    Hamad N
    type
    Author
  7. name
    Kato K
    type
    Author
  8. name
    Sureda A
    type
    Author
  9. name
    Greil R
    type
    Author
  10. name
    Thieblemont C
    type
    Author
  11. name
    Morschhauser F
    type
    Author
  12. name
    Janz M
    type
    Author
bibliography ids
  1. nci-bib-0abecc207cdfbe9166f66392
book metadata
content sha256
d51847fe245eaf1eb8702d2ca45252b262962855f8e70211e81c727bbd5ac045
document type
citation
dois
  1. 10.1056/NEJMoa2116596
electronic publication date
display
2021 Dec 14
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34904798
immutable id
pubmed:34904798@d51847fe245eaf1eb8702d2ca45252b262962855f8e70211e81c727bbd5ac045
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
7
name
The New England journal of medicine
nlm unique id
0255562
pages
629-639
volume
386
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2022 Feb 17;386(7):692-696. doi: 10.1056/NEJMe2118899.
    note
    Source null
    related pmid
    34904797
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2022 Feb;19(2):71. doi: 10.1038/s41571-021-00598-7.
    note
    Source null
    related pmid
    34987189
    relationship
    Comment in
outcomes validated
false
pmid
34904798
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
69f43dadec86f35c0be802e9b2ed66a1c0e7579cf49edb763319891e0291200c
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Feb 17
precision
day
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34904798/
title
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.

Preserved source evidence · Independent clinical review pending · Not medical advice